Therapeutic agents for achondroplasia

Abstract

The present invention aims to provide novel therapeutic agents for achondroplasia caused by mutations in FGFR3. Therapeutic agents for achondroplasia caused by the cartilage growth inhibition resulting from mutations in the gene for fibroblast growth factor receptor 3 (FGFR3), comprising a substance activating guanylyl cyclase B (GC-B) as an active ingredient are disclosed.

1 . A therapeutic agent for achondroplasia caused by the cartilage growth inhibition resulting from mutations in the gene for fibroblast growth factor receptor 3 (FGFR3), comprising a substance activating guanylyl cyclase B (GC-B) as an active ingredient.  
     
     
         2 . The agent of  claim 1 , wherein the cartilage growth inhibition is rescued by enlarging hypertrophic chondrocytes and increasing the extracellular matrix of the proliferative chondrocyte layer.  
     
     
         3 . The agent of  claim 1 , wherein the substance activating GC-B is a peptide.  
     
     
         4 . The agent of  claim 3 , wherein the peptide is a C-type natriuretic peptide (CNP).  
     
     
         5 . The agent of  claim 4 , wherein the CNP is CNP-22 or CNP-53.  
     
     
         6 . A method for increasing the size of a bone growth plate in an abnormal bone comprising administering a substance activating guanylyl cyclase B (GC-B).  
     
     
         7 . The method of  claim 6 , wherein the substance activating GC-B is a peptide.  
     
     
         8 . The method of  claim 7 , wherein the peptide is a C-type natriuretic peptide (CNP).  
     
     
         9 . The method of  claim 8 , wherein the CNP is CNP-22 or CNP-53.  
     
     
         10 . A method of elongation of an abnormal bone comprising administering a substance activating guanylyl cyclase B (GC-B).  
     
     
         11 . The method of  claim 10 , wherein the substance activating GC-B is a peptide.  
     
     
         12 . The method of  claim 11 , wherein the peptide is a C-type natriuretic peptide (CNP).  
     
     
         13 . The method of  claim 12 , wherein the CNP is CNP-22 or CNP-53.  
     
     
         14 . A method for rescuing the cartilage growth inhibition by enlarging hypertrophic chondrocytes and increasing the extracellular matrix of the proliferative chondrocyte layer, comprising administering a substance activating guanylyl cyclase B (GC-B).  
     
     
         15 . The method of  claim 14 , wherein the substance activating GC-B is a peptide.  
     
     
         16 . The method of  claim 15 , wherein the peptide is a C-type natriuretic peptide.  
     
     
         17 . The method of  claim 16 , wherein the CNP is CNP-22 or CNP-53.